VXRT - Vaxart's COVID-19 vaccine candidate shows benefit in preclinical studies

Vaxart (VXRT) jumps 20% in premarket, in reaction to additional data from preclinical study evaluating its COVID-19 vaccine candidate.Data showed significant reduction in lung viral load of 4-5 logs in hamsters that received two oral vaccine doses, as compared to non-vaccinated animals.Also, the study demonstrated that mucosal protection by both intranasal and oral routes of administration was comparable.As previously announced, all hamsters that received two oral doses of Vaxart’s COVID-19 vaccine candidate showed no systemic weight loss. Whereas, the unvaccinated animals lost ~9% total weight. Additionally, unvaccinated hamsters had over 2x the relative lung weight of orally vaccinated hamsters.

For further details see:

Vaxart's COVID-19 vaccine candidate shows benefit in preclinical studies